PCN82 COST-EFFECTIVENESS OF NIVOLUMAB AS ADJUVANT TREATMENT OF MELANOMA IN ADULTS WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN THE ITALIAN SETTING

Autor:	Andrea Marcellusi, M. Augusto, A. Amadi, S. Teitsson, F.S. Mennini, I. Orsini, P. Di Rienzo, C. Bini
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty Cost effectiveness business.industry Health Policy Melanoma medicine.medical_treatment Public Health Environmental and Occupational Health Disease medicine.disease Complete resection Internal medicine medicine Lymph Nivolumab business Adjuvant
Zdroj:	Value in Health. 22:S451-S452
ISSN:	1098-3015
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::fdbc188ce222ce7aa5bc9e69a85d5f38 https://doi.org/10.1016/j.jval.2019.09.279 Zobrazit plný text záznamu Full Text from ScienceDirect